| Name | Dabuzalgron |
| Description | Dabuzalgron (Ro 115-1240), an orally active selective alpha-1A adrenergic receptor agonist, is used to treat urinary incontinence and prevents doxorubicin-induced cardiotoxicity by maintaining mitochondrial function. |
| In vitro | Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage. |
| In vivo | Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.29 mM), Sonication is recommended.
DMSO : 25 mg/mL (78.67 mM), Sonication is recommended.
|
| Keywords | α1A-adrenergic receptor | urinary | potential | mitochondrial | membrane | Inhibitor | inhibit | incontinence | death | Dabuzalgron | Cell | Beta Receptor | Apoptosis | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Mitochondria-Targeted Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Drug Library |
United States
